

# Dr Rozenn Allerton, MD, FRCR

---



## Current Appointment

**Retired Consultant Clinical Oncologist (Gynaecology, Breast and Centre Nervous System).**

## Previous Appointments

**Clinical Director of Cancer Services**

**Head of Service for Radiotherapy**

**College Tutor**

## Medico-Legal Experience

Since the early 2000s, I have been an independent medical expert, at the request of solicitors providing reports for both claimants and defendants dealing with breach of duty and causation in my field of expertise on a regular basis.

I have retired to France but still registered to GMC and RCR, as well as still being a member of MPS. I have a license to practice until September 2029 and continue to update my knowledge.

## Education


**MD (1989) Paris** Thesis: Neuroblastoma in Adults


**FRCR (London 1994)**

**Specialist Accreditation** granted 31 May 1996



[contact@cancerlegalexperts.co.uk](mailto:contact@cancerlegalexperts.co.uk)





## Research and Audit

Widespread participation in clinical trials and publications

From 2009 to 2014 I was the **Audit Convener for the Directorate**,

This includes:

- Chairing Monthly Directorate Meeting
- Working with Facilitator and Directorate Governance Lead to produce quarterly plan of audit and evaluate progress
- Attending Monthly Trust Clinical Audit and Effectiveness meeting and feed back to trust and Directorate
- 

I have produced and presented regular audits and reviews to our monthly directorate audit meetings such as:

- Outcome and treatment toxicity of endometrial cancer
- Outcome and treatment toxicity in cervical cancer
- Management of axillary and supraclavicular region in breast cancer – lead to departmental policy
- Use of serum ca125 markers in ovarian cancer to predict outcome of interval debulking surgery
- Adherence to NICE guidance in treatment of ovarian cancer
- Interruption/compensation in radical radiation treatment of cervical cancer
- Outcome and Compliance with NICE for Glioblastoma Multiforme
- Prospective audit following the introduction of HDR treatment for endometrial cancer.
- Treatment pathway and outcome in ovarian cancer at RWH. I contributed and personally presented this abstract at ESGO 2013 Liverpool national meeting. This audit demonstrated best practice and survival outcome similar to published data.
- Chemoradiotherapy with concurrent Temozolomide in glioblastoma multiforme presented in our departmental audit meeting. I contributed to this audit demonstrating best practice and outcome.
- IMRT in Cervical cancer at RWH

Participated in National Audit

- Treatment toxicity in cervical cancer in UK lead by the RCR
- Management of relapsed platinum resistant ovarian cancer

Reviewer for cancer help UK for cervical cancer

**Big recruiter in clinical trials and details of publications available on request**

## References

Available upon request

